Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 janv. 2023 18h20 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 31, 2022...
Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2022 Net Product Revenues
09 janv. 2023 13h28 HE
|
Sarepta Therapeutics, Inc.
- The Company expects to exceed 2022 full-year guidance for net product revenues - Preliminary net product revenues for the fourth quarter and full-year 2022 are expected to total $235.5 million...
Sarepta Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
03 janv. 2023 08h30 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 déc. 2022 17h58 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2022...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30 nov. 2022 18h00 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 30, 2022...
Sarepta Therapeutics Announces That U.S. FDA has Accepted for Filing and Granted Priority Review for the Biologics License Application for SRP-9001, Sarepta’s Gene Therapy for the Treatment of Ambulant Individuals with Duchenne Muscular Dystrophy
28 nov. 2022 07h00 HE
|
Sarepta Therapeutics, Inc.
– Regulatory action date of May 29, 2023 – SRP-9001 would be the first gene therapy for Duchenne, a one-time treatment designed to treat the underlying cause of DMD by delivering a functional...
Sarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference
23 nov. 2022 08h30 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will...
Sarepta Therapeutics Announces Third Quarter 2022 Financial Results and Recent Corporate Developments
02 nov. 2022 16h05 HE
|
Sarepta Therapeutics, Inc.
Total revenues, which consist of net product revenues and collaboration revenues, for the third quarter 2022 totaled $230.3 million Net product revenues for the third quarter 2022 totaled $207.8...
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 oct. 2022 18h00 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on October 31, 2022...
Sarepta Therapeutics to Announce Third Quarter 2022 Financial Results
26 oct. 2022 08h30 HE
|
Sarepta Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2022 financial...